Form 4 for SKIN SkinHealth Systems Inc.
Accepted 2023-11-21 00:00:00 ET · period of report 2023-11-20 · accession 0001628280-23-039740 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-21 | 2023-11-20 | SKIN | BECK MARLA MALCOLM | Interim CEO, Dir | A - Grant | — | +213.7K | 240.6K | +795% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-11-20 | A | A | 213,675 | — | 240,552 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs"). The RSUs vest in equal monthly installments for a period of six months beginning on November 20, 2023 (the "Term"), the vesting commencement date, provided that, in the event the issuer terminates the reporting person prior to the expiration of the Term, all then unvested RSUs shall immediately vest at the time of termination. |